Brazil's new Rio stock exchange to start operations later than expected
RIO DE JANEIRO (Reuters) -A Rio de Janeiro-based stock exchange is expected to begin operations by the end of April 2026, the executive leading the project said on Monday, a delay from initial projections.
The new bourse, called Base Exchange and controlled by Abu Dhabi's Mubadala, could shift Brazil's financial landscape, as Sao Paulo-based stock exchange B3 currently reigns in the Brazilian market.
Claudio Pracownik, CEO at Rio de Janeiro's Base Exchange, told Reuters the revised timeline reflects regulatory processes. Previously, operations were expected to start this year.
Tests for the new exchange have been conducted at the Brazilian securities watchdog CVM, while simulations at the central bank are expected to take place by August, according to Pracownik, who expects to receive the necessary regulatory authorizations by the end of the year.
Base hopes to compete with B3 by using different technology and operating at lower cost, he said. "We are proposing to do better, faster and cheaper."
B3 did not immediately respond to a request for comment.
Pracownik said he has already spoken with representatives of the main companies whose shares trade on B3, and that they showed interest in also trading their shares on the Rio de Janeiro exchange.
"These companies have nothing to lose. Petrobras, Vale, Banco do Brasil and others expressed interest in trading," said Pracownik.
Banco do Brasil and Petrobras did not immediately respond to requests for comment. Vale declined to comment.
The new exchange, which would initially trade assets such as equities, intends to launch new products every eight to nine months, including derivatives and options, to be able to compete with B3, Pracownik added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
E-Scopics' Ultraportable, Software-Based Hepatoscope In Use Across Leading Institutions and Clinics AIX-EN-PROVENCE, France, June 20, 2025--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, "Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it." The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, "We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it." The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. "As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. "I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant." Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, "In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications." E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit View source version on Contacts Dan ConleyBeacon Communicationsdconley@ 312-593-8461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
Saint-Gobain acquires Maturix to expand digital construction reach
French multinational Saint-Gobain has acquired Denmark-based real-time concrete monitoring solutions provider Maturix, marking a significant step in the expansion of its digital construction chemicals platform. Maturix's wireless sensor technology facilitates remote monitoring of concrete properties during the curing and hardening process, which can halve the duration of the concrete construction cycle and enhance job-site efficiency. The integration of the Danish company into Saint-Gobain's portfolio strengthens the company's digital offerings across the concrete and cement value chains. Saint-Gobain customers can now benefit from reduced overdesign and optimised operations, contributing to the digital transformation of the concrete industry. This move follows Saint-Gobain's initiatives such as the deployment of Verifi, its digital in-transit concrete management suite, across North America, Europe, and Asia-Pacific. Verifi's real-time monitoring capabilities are designed to minimise waste, boost operational performance, and drive cost efficiencies. The addition of Maturix's technology is expected to complement Verifi's system, particularly in optimising concrete placement on construction sites. Since 2019, Maturix and Saint-Gobain have collaborated successfully, and they are currently developing a joint product offering. Earlier this year, Saint-Gobain completed the acquisition of FOSROC, a construction chemicals company, which further solidified Saint-Gobain's position in the global market, enhancing its capabilities in the construction chemicals sector. "Saint-Gobain acquires Maturix to expand digital construction reach" was originally created and published by World Construction Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
24 minutes ago
- Business Wire
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
AIX-EN-PROVENCE, France--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, 'Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it.' The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, 'We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it.' The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. 'As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. 'I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant.' Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, 'In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications.' E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit
